Screener
Palvella Therapeutics PVLA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Non-cash interest expense – royalty agreement | 2,039 | 1,215 |
| Change in fair value of derivative liabilities – royalty agreement | 116 | 75 |
| Change in fair value of derivative liabilities – contingent value right liability | (202) | — |
| Stock-based compensation | 3,376 | 1,094 |
| Accretion on marketable securities | (15) | — |
| Non-cash lease operating expense | 44 | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (357) | 819 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's stock-based comp?
- Palvella Therapeutics (PVLA) reported stock-based comp of $3.38M in Q1 2026.
- How has Palvella Therapeutics's stock-based comp changed year-over-year?
- Palvella Therapeutics's stock-based comp increased by 208.6% year-over-year, from $1.09M to $3.38M.
- What is the long-term trend for Palvella Therapeutics's stock-based comp?
- Over 3 years (2021 to 2025), Palvella Therapeutics's stock-based comp has grown at a 7.1% compound annual growth rate (CAGR), from $5.22M to $6.4M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Palvella Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude